A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: A placebo-controlled study in healthy normolipidaemic subjects

British Journal of Clinical Pharmacology

Volumn 41, Issue 5, 1996, Pages 381-387

  Eagles, C J ^a   Kendall, M J ^a   Maxwell, S ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

bezafibrate; exercise; fat oxidation; fluvastatin

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; FATTY ACID; FLUINDOSTATIN; GLYCEROL; LACTIC ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENERGY METABOLISM; EXERCISE; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0029984365     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03415.x     Document Type: Article

References (29)

1. Bergstrom J, Hultman E, Jorfeldt L, Pernow B, Wahren J. Effect of nicotinic acid on working capacity and metabolism of muscle glycogen in man. J Appl Physiol 1989; 26: 170-176.
2. Walker M, Cooper BG, Elliott C, Reed JW, Orskov H, Alberti KG. Role of plasma non-esterified fatty acids during and after exercise. Clin Sci 1991; 81: 319-325.
3. Head A, Jakeman PM, Kendall MJ, Cramb R, Maxwell S. The impact of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers. Postgrad Med J 1993; 69: 197-203.
4. Hermansen L, Hultman E, Saltin B. Muscle glycogen during prolonged severe exercise. Acta Physiol Scand 1967; 71: 129-139.
5. 2 in man. J Appl Physiol 1973; 35: 85-89.
6. Consolazio CF, Johnson RE, Pecora E. Physiological measurements of metabolic functions in man. McGraw Hill, New York; 1963.
7. Stein MW. D-Glucose, determination with hexokinase and glucose-6-phosphate dehydrogenase. In Methods of enzymatic analysis, Bergmeyer HU. (ed) Academic Press, New York, 1963; pp. 117-119.
8. Gloster JA, Harris P. Observations on an enzymatic method for the estimation of pyruvate in blood. Clin Chim Acta 1962; 7: 206.
9. Mulder C, Schouten JA, Popp-Snijers C. Enzymatic colorimetric test for in vitro assay of free fatty acids in serum and plasma. J Clin Chem Biochem 1983; 21: 823-27.
10. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476.
11. Boobis LH, Maughen RJ. A simple one step enzymatic fluorometric method for the determination of glycerol in 20 μl of plasma. Clin Chem Acta 1983; 132: 173-179.
12. Davidson MH. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med 1994; 96 (suppl 6A): 41-44.
13. Greten H, Beil FU, Schneider J, et al. Treatment of primary hypercholesterolaemia: Fluvastatin, a new HMG-CoA-reductase inhibitor, vs bezafibrate. (Abstract). The Hyperlipidaemic Subject and Multiple Risk Factors: A Comprehensive Approach. 62nd EAS Congress Sept. 1993.
14. Ahlborg G, Felig P, Hagenfeldt L, Hendler R, Wahren J. Substrate turnover during prolonged exercise in man. J Clin Invest 1974; 53: 1080-90.
15. Wolfe RR, Klein S, Carraro F, Weber JM. Role of triglyceride-fatty acid cycle in controlling fat metabolism in humans during and after exercise. Am J Physiol 1990; 258: E382-9.
16. Stubbe I, Hansson P, Gustafson A, Nilsson-Ehle P. Plasma lipoproteins and lipolytic enzyme activities during endurance training in sedentary men. Metabolism 1983; 32 (12): 1120-1128.
17. Devlin JT, Barlow J, Horton ES. Whole body and regional fuel metabolism during early post-exercise recovery. Am J Physiol 1989; 256: E167-72.
18. Maragandakis ME, Hankin H. On the mode of action of lipid lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl CoA carboxylase. J Biol Chem 1971; 246: 348-354.
19. Rodney O, Uhlendorf P, Maxwell RE. The hypolipidemic effect of gemfibrozil (CI-719) in laboratory animals. Proc R Soc Med 1976; 69: 6-9.
20. Rifkind BM. Effect of CPIB ester on plasma free fatty acid levels in man. Metabolism 1966; 15: 673-675.
21. Carlsson LA, Walldius G, Butcher BW. Effect of chlorophenoxyisobutyric acid on fat mobilizing lipolysis and cyclic AMP levels in rat epididymal fat. Atherosclerosis 1972; 16: 349-357.
22. Kissebah AH, Adams PW, Harrigan P, Wynn V. The mechanism of clofibrate and tetranicotinylfructose (Bradilan) on the kinetics of plasma free fatty acids and triglyceride transport in type IV and type V hypertriglyceridaemia. Eur J Clin Invest 1974; 4: 163-174.
23. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987; 83 (suppl 5B): 9-20.
24. Vessby B, Lithel H, Ledermann H. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridemic patients with bezafibrate. Atherosclerosis 1982; 44: 113-118.
25. Kesaniemi YA, Grundy SM. Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984; 251: 2241-2246.
26. Kesaniemi YA, Beltz WF, Grundy SM. Comparisons of clofibrate and caloric restriction on transport of very low density lipoprotein triglycerides. Arteriosclerosis 1985; 5: 153-161.
27. Brown MS, Goldstein JL. Drugs used in the treatment of hyperlipoproteinemias. In The pharmacological basis of therapeutics, 8th Ed., eds Gilman AG, Rall TW, Nies AS. New York: Pergamon Press; 1990; pp. 874-896.
28. Bulow J, Madsen J. Regulation of fatty acid mobilization from adipose tissue during exercise. Scand J Spurts Sci 1986; 8: 19-26.
29. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinaemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87 (suppl. III): 45-53.